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Abstract
Purpose: The suitability of [18F]FDG, [18F]FLT, [18F]FET, and [18F]FCH as non-invasive positron
emission tomography (PET) biomarkers for monitoring response to chemotherapy was analyzed
in various experimental tumor models.
Procedures: Tracer uptake into three syngeneic rodent tumor models and ten human xenograft
models was evaluated using semiquantitative analysis of small-animal PET data. Murine RIF-1
fibrosarcomas and [18F]FLT were selected to monitor the effects of the novel cytotoxic
patupilone.
Results: Except [18F]FCH, all tracers provided good tumor visualization. Highest [18F]FDG
uptake was identified in syngeneic tumors. Xenograft models, however, showed low [18F]FDG
SUVs and were better visualized by [18F]FLT. Monitoring the effects of patupilone on [18F]FLT
uptake in RIF-1 tumors revealed a significant decrease of tracer uptake after 24 h, which
strongly negatively correlated with apoptosis.
Conclusion: [18F]FLT PET of experimental tumors is a viable complement to [18F]FDG for
preclinical drug development. [18F]FLT may be an excellent biomarker for patupilone-induced
apoptosis.
Key words: PET, [18F]FDG, [18F]FET, [18F]FCH, [18F]FLT, Tumor xenografts, Quad-HIDAC,
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Introduction
Non-invasive imaging of molecular and biologicalprocesses in living subjects with positron emission
tomography (PET) provides exciting opportunities to mon-
itor metabolism and detect diseases in humans and in small
animal models [1]. The first oncological application using 2-
deoxy-2-[18F]fluoro-glucose ([18F]FDG) for PET imaging of
tumors was almost 25 years ago [2]. Since then, [18F]FDG
has become indispensable for the detection and grading of
tumors and is also increasingly used for the monitoring of
tumor response to therapy [3–5]. Radiolabelled thymidine,
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amino acid or choline derivatives such as 3′-deoxy-3′-[18F]
fluorothymidine ([18F]FLT), [18F]fluoro-ethyl-L-tyrosine
([18F]FET) or [18F]fluorocholine (N,N-dimethyl-N-[18F]fluo-
romethyl-2-hydroxyethylammonium ([18F]FCH) are alterna-
tive PET tracers for tumor diagnosis because these
compounds monitor biochemical pathways of cell prolifer-
ation [6], protein synthesis [7] or membrane assembly [8].
Thymidine is a component consumed by rapidly growing
cells via a salvage pathway for incorporation into DNA [9].
After using different nucleoside transporters, thymidine is
directly phosphorylated by thymidine kinase-1 (TK-1), which
is exclusively expressed in S-phase and further metabolized
into thymidine triphosphate, acting as a substrate for DNA
polymerase [10]. [18F]FLT, an [18F]-labelled analogue of
thymidine, has become an important and promising tracer in
oncology research and clinical practice aside from [18F]FDG
[11–16]. Tumor uptake and retention of [18F]FLT should thus
be a good biomarker of tumor cell proliferation and is considered
to be less influenced by tumor blood flow and nontumor cell
metabolism as has been observed for [18F]FDG [17].
[18F]FET is a fluoro-ethylated derivative that is not
metabolized or incorporated into proteins, contrary to its
template amino acid tyrosine. Sodium-independent amino acid
transporters are responsible for high [18F]FET accumulation in
tumor cells [18]. A successful labeling method and first data in
vitro as well as distribution in a patient were demonstrated by
Wester et al. [19]. Results from larger groups of patients with
[18F]FET are part of the recent literature from 2005/2006
[20, 21], and intensive preclinical research with a more
mechanistic focus was done on brain tumor models such as
C6 rat glioma [22, 23]. It has also been shown that [18F]
FET selectively accumulates in tumors and not in inflam-
matory tissues [24].
Choline and the fluorinated analogue [18F]FCH are
similarly transported into mammalian cells followed by
phosphorylation, interacting with choline kinase, which is
up-regulated in tumor cells. Choline is then metabolized to
phosphatidylcholine, an essential cellular compound needed
to assemble membranes [8]. Initial work, using [11C]choline
and [18F]FCH as PET tracers to demonstrate the diagnostic
potential of these compounds, i.e., diagnosing prostate
tumors as well as lung and brain tumors, has been done by
Degrado et al. [25, 26] and Hara et al. [27–30].
The purpose of this study was to evaluate potential PET
tracer candidates besides [18F]FDG for determining the
optimal biomarker for each of various drug development
candidates with different mechanisms of action. This was
prompted by our observations that human tumor xenografts in
athymic nude mice have a low and heterogeneous [18F]FDG
uptake per se [31], which may limit the sensitivity of this
approach in xenografts. In this report, the standardized uptake
values (SUV) of [18F]FLT, [18F]FET, and [18F]FCH were
compared with [18F]FDG in various experimental tumor
models comprising syngeneic rodent tumors and human
tumor xenografts. Comparisons suggested that in these
experimental models, [18F]FLT was the best tracer since it
provided the highest and most consistent uptake in tumors. As
an example of the application of these pre-clinical compar-
isons of different tracers, we chose to use [18F]FLT PET
imaging to monitor the effect of the novel cytotoxic
compound patupilone (aka Epothilone B, EPO906). Patupi-
lone is a potent microtubule stabilizer [32] currently in phase
II/III clinical development for several different types of solid
tumor [33] and shows strong anti-proliferative action induc-
ing apoptosis in vitro and in vivo [32, 34]. To test the effect of
paputilone on [18F]FLT tumor uptake, we chose the s.c.
murine RIF-1 tumor model, since Leyton et al. [35] had
shown sensitivity for this model using [18F]FLT as a
biomarker to monitor the early effects of treatment of another
cytotoxic, cisplatin. Furthermore, this model was (a) highly
sensitive to patupilone giving the chance of large changes in
[18F]FLT uptake, (b) tolerated the drug very well, thus
minimizing drop-out from the PET experiment over 6 days,
and (c) was easily amenable to ablation and thus
subsequent analysis ex vivo allowing correlation between
PET and immunohistochemistry (IHC). The identification
of [18F]FLT as a non-invasive PET biomarker of tumor
response to patupilone would facilitate development of
this compound and any future clinical application of the
compound.
Materials and Methods
Radiopharmaceuticals
[18F]FDG was obtained from the commercial [18F]FDG production of
the University Hospital Zurich with a specific activity of ca.
1,000 GBq/μmol. [18F]FLT was produced in-house at the Department
of Radiopharmaceutical Science of the Federal Institute of Technology
of Zurich (ETH) according to the procedure reported by Kim et al.
[36]. The specific activity was ca. 250 GBq/μmol. [18F]FET and [18F]
FCH were provided by University Hospital Zurich with specific
activities of ca. 200 GBq/μmol and 100 GBq/μmol, respectively. [18F]
FET was produced using the method published by Wester et al. [19],
[18F]FCH was synthesized as described by Spaeth et al. [7].
Animal Handling
All experiments were carried out according to procedures covered
by permit numbers (BS 1974/75) and approved by the Kantonales
Veterinäramt Zurich and strictly adhered to the Federal animal
protection law and the “Eidgenössische Tierschutzverordnung”.
Female Brown-Norway (BN) rats, C3H/He and C57BL/6 mice
were obtained from Charles River (France) and female Harlan Hsd:
Npa nu/nu (nude) athymic mice were obtained from the Novartis
breeding stock. Rats weighed between 135 and 180 g, whereas mice
weighed 20–30 g prior to experiments. Depending on the growth rate
of the tumor, animals were shipped to the imaging facility site
2–4 weeks after preparation, using appropriate transfer conditions.
All animals were randomized based upon body weight and
tumor volume measured beforehand by calipers. Animals were
identified by tail and back labels or shaving and kept in groups of
six to ten mice or three to five rats, respectively, under normal
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conditions with access to food and water ad libitum. Animals were
killed by CO2 inhalation (mice) or decapitation (rats).
Tumor Models
Mouse B16/BL6 metastatic melanoma were created as described
[37]. Cells were cultured in supplemented minimum essential medium
(2 mmol/L glutamine, 5% fetal calf serum (FCS), 1% sodium
pyruvate, 1% nonessential amino acids, and 2% vitamins) and kept
at confluence for 4–5 days (with a medium change every 48 h) before
resuspension in Hank’s balanced salt solution (+10% FCS). Using a
Hamilton syringe, 5×104 cells were injected intradermally (i.d.) in a
volume of 1 μL into the dorsal pinna of both ears of anesthetized
C57BL/6 mice. After 1 week, the primary tumor was visible as a black
dot in the middle of the ear, and after 10 days, the cervical lymph node
metastases were detectable by palpitation. Mice were used for PET
studies ca. 14 days after cell inoculation.
Murine RIF-1 fibrosarcoma cells were obtained as a gift from
Ms Loreta Rodrigues (St George’s Hospital Medical School,
London, UK). Cells were cultured in RPMI medium supplemented
with 10% FCS and 5×106 cells per mouse were injected
subcutaneously (50 μL phosphate-buffered saline (PBS)) in the
upper thigh of anesthetized female C3H/He mice. After 10–14 days,
tumors were of sufficient size for PET studies.
BN472 rat mammary carcinoma tumors were created by
transplantation of tumor fragments as described [38]. Briefly, frozen
tissue or fresh tumor samples from earlier in-house studies were
washed sterilely in saline containing 100 μg/mL gentamicin and then
placed in a Petri dish containing Ham’s F-12 medium with 100 μg/mL
gentamicin and 10% FCS. The tumor tissue was divided into small
pieces (3×3×3 mm), and one piece was inserted into a hole made
by a 22-gauge sterile needle in the lowest mammary fat pad of
anesthetized rats after wiping the skin with 70% alcohol. The hole
was closed with two metal wound clips which were then removed
after 3–4 days.
The human NSCLC cell line NCI-H-460 was obtained from the
American Type Culture Collection and a stable luciferized version
created in Novartis by retroviral infection. Using athymic nude
mice, two different brain tumor models were evaluated as follows.
(1) H-460-Luc cells (5×104 in 10 μL PBS) were injected
intracranially (i.c.) in the cortex. (2) Orthotopic lung model with
spontaneous metastases to the lymph-nodes as well as brain: H-
460-Luc cells (105 in 100 μL of Ca and Mg-free PBS) were
injected into the pleural cavity. This number of cells permitted
growth over a reasonable time without impacting too rapidly on
mouse health, and lymph-node metastases (neck and legs)
including some micro brain metastases appeared ca. 2 weeks later.
Prior to PET experiments, growth was monitored non-invasively
using the IVISTM-imaging system (Caliper, USA), and quantifica-
tion of light emission was made with the Living ImageTMv2.20
software package by injecting the mice i.p. with 150 mg/kg of D-
Luciferinin in PBS (10 ml/kg) 15–20 min prior to imaging. Shipment
to the PET imaging facility was done when the bioluminescent
(BioL) signal was 9106photons/s (5–7 days post cell injection).
The human NSCLC cell line NCI-H-596 was grown in RPMI-
1640 medium supplemented with 10% FCS and 1% glutamine. Cells
were grown to confluence before trypsination and re-suspension in
Ca2+- and Mg2+-free PBS. Cells were injected s.c. in the flank of
athymic nude mice at a concentration of 5×106 cells per animal in a
volume of 50 μL in PBS under anesthesia. After 6–12 weeks growth,
tumors were transplanted by ablating the tumor and dissecting the
nonnecrotic material in culture medium. In a sterile environment,
40 mm3 of solid tumor material was placed s.c. into fresh mice under
anesthesia. Further passages of the tumor weremade by transplantation.
All other human tumor xenografts grown in athymic nude mice
were created by injection of cells. Various different cell lines
(HCT-116 colon carcinoma, NCI-H-460 lung adenocarcinoma, KB-
31 cervical epidermoid carcinoma, DU-145 prostate carcinoma,
HT-29 colon adenocarcinoma, SKOV-3 ovarian carcinoma and
U87 MG glioblastoma) were grown in high glucose medium
(Dulbecco’s modified essential medium) supplemented with 10%
FCS, 1% glutamine, 1% sodium pyruvate, and the 1% antibiotics
(penicillin and streptomycin). At confluence, cells were trypsinized
and injected s.c. (dorsal axillary region) in 50–100 μL (≥2×106
cells) of PBS (Na+- and Mg2+-free) in the anesthetized animal.
In general, tumors grown at the skin were allowed to reach sizes
of ≥200 mm3 prior to PET imaging. However, due to different
growth rates of the tumor models and the availability of scanner time,
sometimes smaller tumors were used of 50–100 mm3 and occasion-
ally 10–50 mm3 particularly for the i.c. tumors (H-460-Luc).
However, in all cases, the PET system used (see below) was able
to visualize these tumors with the appropriate tracer.
Drug Preparation and Treatment
Patupilone was obtained from Chemical Development, Novartis
(Basel, Switzerland), and the powder was stored at −20°C. It was
freshly prepared on each treatment day by dissolving in polyethylene
glycol-300 (PEG-300) and then diluting with physiological saline
(0.9% (w/v) NaCl) to obtain a mixture of 30% (v/v) PEG-300 and
70% (v/v) physiological saline for i.v. administration in the tail vein. The
injection volumewas 5mL/kg for mice and 2mL/kg for rats. Treatment
with vehicle (PEG-300/saline) or patupilone was once weekly.
Several different experiments were performed with patupilone,
where mice were treated i.v. with either patupilone (1–5 mg/kg) or
the patupilone-vehicle (vehicle). In the two BioL experiments using
human H-460-Luc cells in athymic mice (Fig. 1), animals were
divided into two groups (n=10 per group) and were treated once
with vehicle or patupilone (4 mg/kg). In the dose–response
experiment using murine RIF-1 tumors, mice were divided into
four groups (n=8 per group) and treated once with vehicle or
patupilone at 1, 3, or 5 mg/kg (Fig. 7). For the longitudinal [18F]
FLT experiment with extensive IHC (Figs. 8 and 9), mice were
divided into two groups (n=20 per group) and treated with vehicle or
patupilone (5 mg/kg). The same mice were studied by PET at baseline
(day 0) as at 24 h when the mice were killed and the tumors ablated for
IHC. The remaining 30mice (five mice for each treatment group) were
studied by PET prior to IHC at the subsequent three different time
points posttreatment. This experimental protocol permitted correlation
of IHC with [18F]FLT at each time point posttreatment.
Animal Monitoring
During the experiments, body weight (BW in grams) and tumor
volume (TVol in cubic millimeter) were measured three times per
week. Tumor dimensions were measured using a caliper, and TVol
was calculated by the following equation: TVol=(pi/6)×x×y×z,
where x, y, and z represent the three orthogonal axes of the tumor.
Efficacy was assessed as the T/C from the change (subtraction) in
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TVol from day 0 (patupilone treatment) to the endpoint (at 1 week
posttreatment initiation), T/CTVol=ΔTVol(treated)/ΔTVol(control). In a
similar manner, the effect of the drug on BW was also quantified,
i.e., the fractional change in BW, ΔF-BW (BWafter/BWbefore), for
both vehicle-control and drug-treated groups was determined and
applied as follows: T/CBW=ΔF-BW(treated)/ΔF-BW(control).
Small Animal PET Study, Image Acquisition,
and Reconstruction
All PET experiments were performed at the Animal Imaging Center of
ETH Zurich at the Center for Radiopharmaceutical Science using the
Fig. 1. Growth of human lung H-460-Luc cells in athymic nude mice as assessed by bioluminescence and the effect of
patupilone. H-460 cells stably expressing the enzyme luciferase were injected intracranially or orthotopically (pleural cavity of
lung) as described in “Materials and Methods”. Luciferin (150 mg/kg) was injected intraperitoneally 15–20 min prior to image
acquisition using the IVISTM imaging system. Mice were treated once by patupilone (4 mg/kg i.v.) on day 5. BioL, in photons/
sec, is expressed as mean±SEM (n=10) per group (open squares vehicle, filled circles PAT-treated) where asterisk signifies
significantly different (PG0.05) from vehicle at all time points posttreatment. Figures show BioL quantified at different time
points from a the head following i.c. injection, and b the lung following pleural injection and an example of the BioL in a mouse
12 days after cell injection in the pleural cavity of the lung (c).
Table 1. Summary of [18F]FDG, [18F]FLT, [18F]FET, and [18F]FCH SUVs in various experimental rodent tumor models
SUV ratio [18F]FDG versus
Tumor model (histotype) Species (host) [18F]FDG SUVa TVol (mm3)a [18F]FLT SUVa TVol (mm3)a
B16/BL6 ortho (Melanoma) Mouse (C57BL/6) 2.06±1.13 (19) 93±62 0.27±0.04 (8) 295±234
RIF-1 s.c. (Fibrosarcoma) Mouse (C3H-He) 0.62±0.21 (4) 295±112 0.56±0.22 (16) 1480±1102
BN472 ortho (Breast) Rat (BN) 0.85±0.21 (63) 1952±1760 0.43±0.09 (6) 10664±3020
H-460 ortho (NSCLC) Human (Nude mice) nd (12) – 0.56±0.06 (4) 249±103
H-460 i.c. (NSCLC) Human (Nude mice) nd (6) – 1.32±0.34 (7) 14±9
H-460 s.c. (NSCLC) Human (Nude mice) 0.22±0.08 (4) 455±65 0.72± 0.24 (8) 307±223
H-596 s.c. (NSCLC) Human (Nude mice) 0.22±0.05 (38) 275±170 0.70±0.16 (68) 237±123
HCT-116 s.c. (Colon) Human (Nude mice) 0.22±0.04 (43) 59±40 0.74±0.13 (48) 68±57
SKOV-3 s.c. (Ovarian) Human (Nude mice) 0.26±0.02 (4) 307±129 0.44±0.08 (5) 346±244
U87MG s.c. (Glioma) Human (Nude mice) 0.55±0.16 (9) 101±81 0.37±0.09 (18) 479±120
HT-29 s.c. (Colon) Human (Nude mice) 0.18±0.02 (2) 234±76 0.53±0.08 (5) 172±93
KB-31 s.c. (Cervix) Human (Nude mice) 0.19±0.04 (17) 261±143 0.38±0.07 (5) 437±421
DU-145 s.c. (Prostate) Human (Nude mice) 0.25 (1) 480 – –
An empty cell means not measured
SUV standardized uptake value, TVol tumor volume as calculated by ROI analysis (PMOD), ortho orthotopic, i.c. intracranial, s.c. subcutaneous, nd not
detectable
aSUV and TVol are shown as mean±SEM, the number of animals used are given in brackets
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dedicated 16-module quad-HIDAC tomograph with a sub-millimetre
resolution (Oxford Positron Systems; Weston-on-the-Green, UK) [38,
39]. The field of view of 280 mm axially and 170 mm in diameter
allowed the acquisition of whole animal body images in a single bed
position. For each tracer, extensive PET experiments were performed
beforehand to determine the optimal injection and acquisition
protocol. These analyses revealed that the use of fasting protocols
and anesthesia during the tracer distribution and uptake phase did not
significantly increase tracer accumulation. In contrast, these protocols
rather enhanced the variability of tracer uptake since fasting states and
anesthesia levels cannot be fully harmonized in a cohort of animals.
Therefore, each tracer (5-30 MBq; 150 μL) was injected i.v. in the
nonfasted, restrained animal allowing distribution and accumulation of
the radiotracer in the non-anesthetized animals, i.e., under physiolog-
ical conditions. For injection into mice, sterile 25-gauge needles were
used. For rats, catheter-assisted injections were performed (Vasofix,
Braunüle™). In both cases, injected doses were precisely quantified by
measuring syringes before and after radiotracer application. Animals
with problematic or questionable injections were excluded from the
quantitative analysis. Following tracer injection; at 8 min for [18F]FCH
and [18F]FET or at 20 min for [18F]FDG and [18F]FLT; the animals
were anesthetized with isoflurane (Forene, Abbott Laboratories; North
Chicago, USA) in an air/oxygen mixture and fixed on the scanner bed
(routinely two mice or one rat), and PET acquisition was initiated
15 min ([18F]FET, [18F]FCH) or 30 min ([18F]FDG, [18F]FLT) after
injection. A warm air stream was used to assure thermostasis at 37°C
body temperature, measured by a rectal sensor. Depth of anesthesia
was controlled by monitoring respiratory frequency using a dedicated
thorax belt.
Raw data files were acquired in list-mode and reconstructed in single
time frame using the OPL-EM algorithm (i.e., voxel size of 0.125 mm3
andmatrix size of 120×120×100 for mouse double scanning and 240×
240×200 for rats) [40]. Reconstruction did not include scatter, random,
and attenuation correction. A simultaneous Na-22 point source
measurement was used as internal standard to correct the reconstructed
image data sets for possible variabilities in scanner sensitivity.
Image Analysis and Quantification
Reconstructed PET images were visually inspected in three dimen-
sions throughout the body and evaluated by a region-of-interest
(ROI) analysis using the dedicated biomedical image quantification
software PMOD (Pmod Technologies Ltd, Adliswil Switzerland)
[41]. ROIs were drawn manually in all coronal slices comprising the
tumor, thus providing volume and average activity concentration of
the entire tumor. The average activity concentration in the tumor was
then normalized to the injected dose per body weight and expressed
as an average standardized uptake value. An alternative approach
using the 5% hottest voxels to provide the “maximum SUV” in a
tumor was not found to be superior, and experience showed it gave
the same results for compound effects on the various tracers.
Tumor Dissection, Histology,
and Immunohistochemistry Analysis of Ki67,
Proliferating Cell Nuclear Antigen, and Caspase-3
In the [18F]FLT experiment, the activity of patupilone was
monitored, and histology and immunohistochemistry were per-
formed at several time points of 1, 2, 3, and 6 days posttreatment
(n=10 mice per time point). The mice were killed by CO2 inhalation,
and tumor slices were harvested from the largest circumference of
the tumor, fixed in 4% phosphate-buffered formaldehyde for 24 h at
4°C, and processed into paraffin as previously described [38].
IHC was performed on paraffin sections and used the following
antibodies for detection of: (1) Caspase-3, (ASP175, Cell Signal-
ling, Danvers, MA, USA), (2) proliferating cell nuclear antigen
(PCNA; ab29, Abcam, Cambridge, UK), and (3) Ki67 antigen
(ab833, Ki67 at 1:100—Abcam, Cambridge, UK).
Microwave-assisted antigen retrieval was carried out for 20 min
(caspase-3 and PCNA) or 40 min (Ki67) in 10 mM citrate buffer,
pH 6.0. After washing in Tris-buffered saline (TBS), endogenous
peroxidase was quenched with 0.5% H2O2 in methanol for 20 min
at room temperature. Slides were further incubated with primary
antibody: (1) overnight (room temperature) caspase-3 diluted 1/75
or Ki67 diluted 1/100 and (2) 1 h (room temperature) with PCNA
diluted 1/2,000. Negative controls were incubated without primary
antibody. After washing in TBS, sections were incubated with
biotinylated serums followed by avidin–biotin horseradish peroxi-
dase complex (Dako, Glostrup, Denmark). Peroxidase activity was
visualized by incubation in a solution of 3.3′-diaminobenzidine
tetrahydrochloride (Medite, Nunningen, Switzerland). Sections were
counterstained with Mayer’s hematoxylin and mounted with Pertex
(Medite). Slides were examined with a light microscope (Nikon,
Eclipse 600) equipped with a motorized stage, connected to a 3CCD
color video camera (Sony, DXC-970 MD). Detection of apoptotic or
proliferating nuclei was done automatically using the software
“Histolab” (Microvision Instruments). Approximately three to nine
frames, covering approximately 10% of the total tumor area, were
captured at ×400 magnification in a nonnecrotic and nonhemor-
rhagic area. The color corresponding to the apoptotic or proliferating
nuclei staining and to the non-apoptotic or nonproliferating nuclei
[18F]FET SUVa TVol (mm3)a [18F]FCH SUVa TVol (mm3)a SUV ratio [18F]FLT [18F]FDG [18F]FET Versus tracer [18F]FCT
0.84±0.16 (4) 339±142 0.54±0.06 (3) 184±51 0.13 0.41 0.26
0.59±0.08 (4) 259±88 0.39±0.06 (4) 128±49 0.90 0.95 0.63
0.64±0.08 (5) 21353±7824 0.27±0.05 (5) 16686±5620 0.51 0.75 0.32
– – – – – – –
0.75±0.21 (3) 6.9±4.3 nd (4) – – – –
0.61±0.28 (8) 303±178 0.21±0.07 (8) 212±149 3.27 2.77 0.95
0.73±0.04 (4) 190±12 nd (4) – 3.18 3.32 –
0.42±0.06 (4) 207±154 0.20±0.01 (4) 108±81 3.36 1.91 0.91
– – – – 1.69 – –
– – – – 0.67 – –
– – – – 2.94 – –
– – – – 1.73 – –
– – nd (6) – – – –
] [18F]FET ersus tracer [18F] CT
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one were defined by using the HSI color space, and the percentage of
apoptotic or proliferating nuclei was calculated.
Graphics and Statistics
Figures and Table show the mean±SEM, unless stated, and the
significance value was set at PG0.05. To test reproducibility of the
tracer uptake over more than two studies, a one-way analysis of variance
(1W-ANOVA) was performed. To determine the significance of the
effect of patupilone treatment, differences between the means of the
various parameters measured (TVol, BW, FLT, caspase-3, Ki67, and
PCNA) were determined using the raw values, and a 1W- or 2W-
ANOVA as appropriate with Tukey post hoc. In addition, the effects at
different time points were summarized as the treatment/vehicle–control
ratio (T/C), i.e., mean value of drug-treated group divided by the mean
value of the control group. Correlation between IHC ex vivo and [18F]
FLT in vivo was tested by linear regression to provide the R and P
values. All analyses used the SigmaStat v3.1 software. To correct for
multiple correlations in the large [18F]FLT IHC experiment (six were
made of [18F]FLT versus Ki67, PCNA and, caspase-3 on day 1 and on
all time points pooled), a Bonferroni test was applied, i.e., P value
multiplied by six.
Results
Tumor Growth
The human tumor s.c. models (H-460, HCT-116, KB-31,
DU-145, HT-29, SKOV-3, U87 MG) xenografted into nude
athymic mice grew with a doubling time of 2–4 days, and
tumors reached a suitable size for imaging 2–3 weeks post
cell injection or transplantation (see, for example, O’Reilly
et al 2008 [42]). The exception was the H-596 model which
grew much more slowly, only doubling in size every 7–
Fig. 2. Tracer uptake in the syngeneic B16/BL6 melanoma tumor model (C57BL/6 mice): a lymph-node metastases and b
primary ear tumors. Results show a [18F]-PET biodistribution of the tracer in a representative coronal slice of the mouse
including lymph node tumor metastases as highlighted in the red box in the right neck area. Red arrows indicate the different
tracers in the tumor. Related coronal slices of [18F]FLT, [18F]FET, and [18F]FCH are shown in the smaller images only showing
head/neck area including lymph node (LN) metastases. Ear melanomas measured with all tracers (b) appeared as spots on
coronal slides (crop of the head/neck area). All images are normalized to the same SUV color scale.
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10 days. The syngeneic rodent tumor models also had
doubling times of 2–3 days as has previously been described
for B16/BL6 [37], RIF-1 [43], and BN472 [34]. The models
where human lung H-460-Luc cells were grown intracrani-
ally (i.c.) or orthotopically have not previously been
described, and their growth as monitored by biolumines-
cence and the effect of a single dose of patupilone (4 mg/kg
i.v.) is shown in Fig. 1. In both models, BioL was
quantifiable ca. 5 days after cell injection and, if the mice
were untreated, tumor growth proceeded rapidly, and mice
had to be culled 12–14 days post cell injection.
FDG Uptake
We had previously observed that [18F]FDG PET of the
human tumor models H-596, KB-31, and HT-29 showed
rather low tracer uptake [31]. Here, we have screened
additional tumor models for [18F]FDG uptake and compared
them as shown in Table 1. [18F]FDG SUV did not correlate
with the respective tumor volume as demonstrated by linear
regressions for each tumor model (R≤0.2, P90.2).
The results showed large differences in [18F]FDG SUV
when compared across the different tumor models. Highest
[18F]FDG uptake was identified in the syngeneic orthotopic
models of B16/BL6 (Fig. 2a, b) and BN472 (Fig. 3a) and also
in the RIF-1 model (Fig. 3b), which could be considered
orthotopic because it is a fibrosarcoma grown s.c. All the other
ten models tested were human tumor xenografts grown in nude
athymic mice and showed low [18F]FDG SUVs of 0.18–0.26,
apart from the s.c. glioma U87 MG tumor model, which
provided a good tumor visualization (mean SUV of 0.55). In
general, human tumor xenografts showed a higher tracer
activity accumulation in the tumor rim compared to the central
area (Figs. 4 and 5), and the tracer uptake became increasingly
rim-limited as the tumor became larger. Thus, although the
tumors could be distinguished from their respective back-
ground and surrounding tissue, the relatively low uptake meant
that determination of a significant drug-induced decrease in
[18F]FDG would be difficult unless these were large effects of
at least 30%. In the human lung tumor H-460-Luc grown
orthotopically or intracranially (i.c.), no [18F]FDG uptake was
measurable at all (Fig. 4a, c), and there was no correlation
between [18F]FDG and TVol (R≤0.18, P≥0.27).
Uptake of [18F]FLT, [18F]FET, and [18F]FCH
Table 1 summarizes the data, and original representative
images are shown in Figs. 2, 3, 4, and 5. Seven different tumor
models (B16/BL6, RIF-1, H-596, BN472, H-460-Luc i.c.,
HCT-116, H-460 s.c.) were compared for uptake of the tracers
[18F]FLT, [18F]FET, and [18F]FCH. Moreover, additional
tumor models (H-460 ortho, SKOV-3, U87 MG, HT-29, and
KB-31) underwent [18F]FLT PET to attain further information
for this particular tracer and to compare it with [18F]FDG.
Finally, the mean SUVs of the different tracers were expressed
as ratios to their respective [18F]FDG SUV as also shown in
Table 1 to compare relative uptake of the tracers.
In contrast to the results for [18F]FDG described above,
relatively low [18F]FLT uptake was observed for the two
syngeneic orthotopic tumors of BN472 in rats (Fig. 3a) and
Fig. 3. Tracer uptake pattern into a rat BN472 mammary tumors (BN rats) and b RIF-1 mouse fibrosarcoma (C3H/He mice).
Results shown for a and b are prominent [18F]FDG PET images displaying the typical biodistribution of the tracer in a
representative coronal slice, including the tumor highlighted in a red box. Red arrows indicate the different tracers in the tumor.
Related coronal slices of [18F]FLT, [18F]FET, and [18F]FCH are displayed as cropped images, including only the tumor area
(lower belly or right flank). All images are normalized to the same SUV color scale.
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B16/BL6 in mice (Fig. 2a, b), even though for the latter
model, the primary (ear) and main metastases (cervical
lymph node) could be clearly visualized. A comparison of
the [18F]FLT and [18F]FDG uptake (SUVs) in the same
model to give an [18F]FLT/[18F]FDG ratio permitted
comparison between models to emphasize that some models
apparently metabolized [18F]FDG more than [18F]FLT,
while for others, the opposite was the case. Thus, in the
BN472 and B16/BL6 models, the [18F]FLT/[18F]FDG ratios
were 0.51 and 0.13, respectively, indicating more [18F]FDG
than [18F]FLT uptake. The other syngeneic orthotopic
model, RIF-1 in mice, provided good visualization by [18F]
FLT; ([18F]FLT/[18F]FDG ratio=0.9) and in all three
models, the [18F]FLT uptake was fairly consistent. Again,
in marked contrast to the results for [18F]FDG, the s.c.
human tumor xenografts in athymic mice had a reasonable
accumulation of [18F]FLT (SUV range of 0.37–0.78) and
consequently higher [18F]FLT/[18F]FDG ratios of 1.7–3.3,
the exception being U87MG, which had the lowest values
for [18F]FLT uptake but the highest values for [18F]FDG of
the s.c. xenografts. In general, the xenograft images for [18F]
FLT were fairly heterogeneous and “spotty,” i.e., regions of
high and low intensity distributed across the tumor but not
necessarily rim-limited (Figs. 4 and 5).
The tumor model with the strongest [18F]FLT uptake was
the human H-460 lung tumor grown i.c. in nude mice, with a
very intense tracer accumulation (SUV of 1.3) providing
excellent visualization (Fig. 4a), much better in comparison
to the same tumor grown orthotopically in the mouse lung
(Fig. 4c). This tumor was poorly visualized by [18F]FDG
also when grown s.c. (Fig. 4b). It could be detected by [18F]
FET but rather poorly by [18F]FCH (Fig. 4).
In general, [18F]FCH provided very poor visualization
(Figs. 2, 3, 4, and 5), with by far the best tracer uptake
Fig. 4. Tracer uptake pattern into athymic nude mice bearing H-460 human lung tumor. The H-460 tumor grown a
intracranially, b subcutaneously, and c orthotopically in the lung. Images in b and c are normalized to the same SUV color
scale. Results show a [18F]FDG PET performed on i.c. growing tumors, displaying biodistribution of the tracer in a
representative coronal slice including tumor (no visualization by [18F]FDG), as highlighted in the red box in the brain/neck area.
Red arrows indicate the tumor for each tracer. Related coronal slices of [18F]FLT, [18F]FET, and [18F]FCH are shown in the
cropped images, only focussing on the brain area, partly including tracer uptake in the tumor. Visualization of tumors from cells
growing s.c. (b) are indicated (right flank area) on a single coronal slice for each tracer for direct comparison. c A series of
merged coronal slices, including [18F]FDG (green/blue signal) and [18F]FLT (red signal) information for differentiation of heart
muscle tissue from solid lung tumor tissue. Moreover, three representative coronal slices for both [18F]FDG and [18F]FLT
displaying midbrain overview are shown in order to reveal possible brain metastases of this particular tumor model.
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Fig. 5. Tracer uptake into athymic nude mice bearing human s.c. xenografts. Representative coronal slices are shown
including a central display of the tumor of a HCT-116 colon carcinoma and b H-596 lung tumor. Results shown in a and b
summarize [18F]FDG PET displaying biodistribution of the tracer including the tumor, highlighted in the red box. Red arrows
indicate the different tracers for each tumor: [18F]FLT, [18F]FET, and [18F]FCH are shown in the smaller images only showing the
areas including tumors (sometimes showing organs such as kidneys). All images are normalized to the same SUV color scale.
Fig. 6. Examples of the reproducibility of [18F]FDG and [18F]FLT in experimental tumor models. Results show individual [18F]
FLT and [18F]FDG SUVs and the associated mean±SEM in three different tumor models from several independent experiments
over 3 years. a Five studies with BN472 for [18F]FDG, b four studies with H-596 using [18F]FLT, c three studies each with HCT-
116 for [18F]FDG, and d for [18F]FLT. Differences between means in each graph were tested using a 1W-ANOVA with Tukey
post hoc; *P=0.01 between Exp-3 and Exp-4 using [18F]FLT on H-596 tumors. Data are also summarized in Table 1.
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detectable in the B16/BL6 model (ear and lymph node). In
the other models, tumors were detectable using [18F]FCH in
only five out of the eight models investigated (Table 1).
Visualization of tumors with [18F]FET was possible in all
seven models and was fairly invariant across the different
models (SUV 0.42–0.84), although images were “spotty”
and showed low intensity. The highest uptake was again in
the B16/BL6 model (Fig. 2a, b), where both the primary
tumor and metastases could be seen.
In summary, of the four tracers compared in these
experimental models, [18F]FLT appeared to be the best
PET tracer since it provided good visualization in all models
with sufficient tracer uptake to expect feasible detection of
drug-induced decreases in SUV.
Reproducibility of [18F]FDG and [18F]FLT
Uptake in Several Different Studies
Both [18F]FDG and [18F]FLT were used in several different
PET studies over 3 years. In order to attain an idea of the
inter-experimental variability over this time, the SUVs were
compared in rat BN472 tumors and the two human tumor
xenografts of H-596 and HCT-116 in athymic nude mice. As
Fig. 6 shows, the intra-experimental variability was greater
than the inter-experimental variability so that the mean
SUVs were fairly invariant over time, and only one (minor)
statistically significant difference was detectable, between
two of the four [18F]FLT experiments using H-596 tumors.
[18F]FLT Response to Anticancer Therapy
with Patupilone in RIF-1-Bearing C3H Mice
Patupilone dose-dependently inhibited growth of RIF-1
tumors giving, after 6 days, a T/CTVol of 1.0, 0.40, and
0.26 for the doses of 1, 3, and 5 mg/kg, respectively
(Fig. 7a). Treatment was well tolerated with no body-weight
loss over the whole treatment period, but a dose-dependent
effect was apparent in comparison to vehicle: T/CBW=0.99,
0.95, and 0.90 for 1, 3, and 5 mg/kg, respectively (Fig. 7b).
Thus, the highest patupilone dose of 5 mg/kg was selected
for the [18F]FLT PET experiment.
A preliminary PET experiment with 12 C3H/He mice
bearing RIF-1 tumors showed that patupilone caused a
significant (P=0.002) decrease in [18F]FLT (T/CFLT=0.78, i.e.,
22% decrease compared to vehicle) after just 24 h. Immuno-
histochemistry experiments ex vivo showed that both markers
for proliferation, %Ki67 and %PCNA, were also decreased (T/
Cs=0.86 and 0.80, respectively), and the [18F]FLT SUV on
day 1 correlated significantly with %Ki67 (R=0.65, P=0.02)
but not %PCNA.
A second experiment using 40 mice is summarized in
Fig. 8. This experiment confirmed that patupilone rapidly
and highly significantly (PG0.001) decreased the [18F]FLT
SUV after just 24 h, and this was followed by a slow
recovery, but the SUVs remained significantly below those
of the vehicle-treated mice. Broadly speaking, these
decreases in [18F]FLT uptake were paralleled by decreases
in %Ki67, but the effects were smaller and did not reach
significance at any single time point, although over the
entire treatment period, there was a significant effect (P=
0.03, 2W-ANOVA). Oddly, there was overall a significant
increase in PCNA (P=0.02) that was highly significant on
day 3 (T/CPCNA=1.5, P=0.002). As expected, there was a
significant increase in apoptosis (caspase-3) induced by
patupilone which was highly significant overall and most
prominent on day 1 (T/CPCNA=2.2, P=0.004). In this
experiment, the patupilone treatment was also considered
well tolerated because there was no loss in body weight.
Correlations between the various IHC ex vivo parameters
and [18F]FLT uptake in vivo revealed a weak positive
correlation between %Ki67 and [18F]FLT on day 1 (R=0.57,
P=0.09, n=10), but none at all over the whole course of the
experiment (R=0.1, P=0.5, n=39; Fig. 9a). In contrast, there
was a very strong negative correlation between apoptosis and
[18F]FLT on day 1 (R=-0.88, P=0.0009, Fig. 9b) and over the
whole time course (R=-0.72, PG0.0001, Fig. 9c). For PCNA,
Fig. 7. Efficacy and tolerability of patupilone in C3H/He
mice bearing RIF-1 fibrosarcomas. Tumors were treated with
patupilone once on day 0 (1, 3, or 5 mg/kg) or vehicle.
Results show the mean±SEM (n=8) for the tumor volume (a)
and body weight (b) for vehicle and patupilone treated mice;
*PG0.05 significantly different from vehicle at the endpoint on
day 6 (1W-ANOVA with Tukey post hoc).
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there was a moderate negative correlation between [18F]FLT
and %PCNA (R=−0.43, P=0.006, Fig. 9d) but no correla-
tion at 24 h (R=−0.33, P=0.35, n=10). These correlations
remained significant even when applying a Bonferroni
correction for the six correlations tested (6×P). Thus, non-
invasive measurement of [18F]FLT appeared to be an
excellent marker of apoptosis induced by patupilone in
RIF-1 tumors.
Discussion
By testing a large panel of 13 different tumor models, it has
been possible to confirm our preliminary impression [31]
that [18F]FDG PET imaging gives low and rim-limited tracer
uptake, especially in human tumor xenografts. Such models
tend to have an inadequate blood supply, and indeed tumor
blood volume and blood flow has been shown to decrease
with increasing tumor size [42], and consistent with this
observation, hypoxia also tends to increase with tumor size
[43]. Thus, our data suggest that the static [18F]FDG PET
images used here may be influenced by blood flow, as are
other imaging techniques using i.v. contrast agents such as
dynamic contrast-enhanced magnetic resonance imaging
(DCE-MRI) [37, 44]. Indeed, the syngeneic orthotopic
models showed the strongest [18F]FDG PET uptake and
have previously been demonstrated to be very well vascu-
larized [34, 37, 45]. Although in this study, we did not show
if a lower blood flow was associated with hypoxia, a
significant correlation has been described in cervical tumors
between tumor oxygenation levels and DCE-MRI [46].
Increased hypoxia has been associated with increased
glycolysis (via HIF-1 transcriptional up-regulation of nu-
merous glycolytic enzymes) but not always so, and a number
of other factors influence glycolysis including the microvas-
culature [47]. Our experience with many models using both
imaging and various histological methods is that human
tumor xenografts have a well-perfused rim, a small rim of
hypoxia next to this and centrally a small to large necrotic
Fig. 8. Longitudinal effect of patupilone on [18F]FLT uptake by s.c. RIF-1 tumors in vivo and comparison with ex vivo IHC
analyses of apoptosis and proliferation. Tumor-bearing C3H/He mice (n=40) were treated with vehicle or patupilone (5 mg/kg,
once i.v.), after which each treatment group was further divided for each time point (n=5 per group per time point). Results
show the mean±SEM (n=5) for the various parameters of [18F]FLT (a), Ki67 (b), caspase-3 (c), and PCNA (d) at the different time
points shown. Differences between means were tested using a 2W-ANOVA with Tukey post hoc. The effect of drug treatment
on the different parameters was summarized as the T/C.
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area (tumor-type dependent). Thus, although there may be
high glucose uptake and glycolysis at the rim, over the
whole tumor, the total [18F]FDG uptake is low.
In general, low and heterogeneous tracer uptake in
experimental tumors represents a complicating factor for
proper PET data interpretation. For [18F]FDG PET imaging
in rodents, various protocols were suggested to increase tumor
uptake [48, 49]. Our own pilot study indicated that tracer
uptake times longer than 30 min, and fasting periods up to 6 h
do not result in a significant increase in tracer accumulation.
We therefore refrained from fasting and focused on a strict
standardization of injection and acquisition protocols to keep
inter-individual variability at a minimum. Additionally, the
quantitative assessment of the heterogeneity of tracer uptake
within a tumor is considered to be another major challenge in
small animal PET imaging. To detect the effect of a drug on the
vital portion of an experimental tumor, the determination of a
“maximum SUV” (only including the hottest voxels of the
tumor ROI) might be more meaningful compared to a ROI
comprising the entire tumor volume. However, when we
directly compared mean SUV with maximum SUV, we found
no difference in the outcome of the effect of a compound. Thus,
we came to the conclusion that such an analysis might be
biased by other factors such as partial volume loss, and we
opted for the average SUV of the whole tumor volume as the
most appropriate indicator of tracer uptake. Clearly, small
animal PET imaging is characterized by limitations such as the
lack of fully quantitative reconstruction software (e.g., correct-
ing for partial volume loss) or the inaccurate ROI delineation in
the absence of any anatomical information. Nevertheless, the
high reproducibility of our [18F]FDG and [18F]FLT uptake
values showing low inter- and intra-experimental variability
(Fig. 6) led us to conclude that the bias of our experimental
approach was in an acceptable range.
In contrast to [18F]FDG, however, with its low and
heterogeneous tracer uptake, two other fluorinated tracers,
[18F]FLT and [18F]FET, showed much more similar intra-
tumor model uptake with adequate to very good visualiza-
tion in all models: 12 for [18F]FLT and seven for [18F]FET,
suggesting, based upon our argumentation above, that the
SUV of these two tracers may be less influenced by the tu-
mor blood supply. Interestingly, the models with the highest
[18F]FDG uptake for the syngeneic orthotopic group (B16/
BL6) or s.c. xenograft group (U87 MG) showed the lowest
[18F]FLT uptake for that group: [18F]FLT/[18F]FDG ratios of
0.13 and 0.67, respectively. The biological significance of
this observation is not known, but it could be interpreted that
high glycolysis is balanced by a lower uptake of thymidine
from that salvage pathway. Uptake of the fluorinated tracer
[18F]FCH was generally rather low or not detectable at all,
even in the human prostate DU-145 tumor model. Again,
observation showed that the best tracer uptake was found in
syngeneic orthotopic tumors. In the one model with a tumor
growing in the brain, H-460 i.c., there was an excellent
accumulation of [18F]FLT, much weaker with [18F]FET, and
not detectable with [18F]FDG or [18F]FCH. Finally, the
mean [18F]FLT uptake and [18F]FDG uptake in a specific
tumor type showed low intragroup variability which would
permit drug-monitoring studies where subtle changes of
tracer uptake need to be identified.
Fig. 9. Correlation of [18F]FLT in vivowith IHC ex vivo. Data are from that shown in Fig. 8 for all time points (a, c,d) or at 24 h only (b),
and the strength of the relationship was measured by linear regression to provide the R value and the significance (P value).
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[18F]FLT PET appeared to provide the best imaging
parameters across all models, and thus we used this tracer as
a non-invasive early-response biomarker to investigate the
effect of the novel microtubule stabilizer patupilone.
Patupilone is a cytotoxic which rapidly inhibits tumor
growth in vivo and causes apoptosis [34, 42], and thus,
[18F]FLT PET seemed to be suitable for this compound
class. We selected the RIF-1 mouse tumor model because of
high sensitivity and very good tolerability of the mice to
patupilone and because ablation for IHC was easier than in
the H-460-Luc model which, although showing a high [18F]
FLT uptake, were very small and difficult to locate. The
results in the RIF-1 tumor showed that patupilone caused the
expected decrease in [18F]FLT already within 24 h, but the
correlation with the proliferation markers Ki67 or PCNA
was relatively weak compared with those in the literature
reviewed by Apisarnthanarax [50]. Actually, both of these
markers are expressed throughout the cell cycle, rather than
just in S-phase, and Ki67 can show higher levels in mitosis
[51], and PCNA may even be expressed by noncycling cells
and has a long half-life [52]. Thus, these markers may not be
ideal for detecting the effect of a drug which causes cells to
accumulate in G2M prior to apoptosis [32]. In contrast,
uptake of [18F]FLT by cells depends predominantly on the
enzyme thymidine kinase-1, which is only expressed in S-
phase [53]. Thus, the best ex vivo marker, or correlate, for
[18F]FLT is really TK-1 [13, 50–53], but this is not routinely
used in the clinic. However, caspase-3 as a marker for
apoptosis is used in the clinic, and the data presented here
showed a very strong correlation between [18F]FLT and
caspase-3.
Conclusions
Our analysis of several different tumor models and four
different fluorinated tracers led us to conclude that, aside
from [18F]FDG, [18F]FLT was likely to be the best all-round
candidate for routine application as an early-response marker
for anti-cancer compounds. [18F]FET also showed some
potential, while on the other hand, [18F]FCH proved not to
be a good generic tracer for animal tumors. As an example,
[18F]FLT was tested in a murine fibrosarcoma using the
novel cytotoxic patupilone, and the results showed that this
tracer was an excellent marker for apoptosis induced by
patupilone, suggesting that this non-invasive technique
could usefully be applied as an early tumor-response marker
for the clinical development of the compound.
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